Table 6.
Adverse events in patients treated with imatinib mesylate (IM) or vinblastine and prednisone (VP) according to VCOG-CTCAE [24].
| Adverse Event * | Grade 1 | Grade 2 | Grades 3–5 | |||
|---|---|---|---|---|---|---|
| IM | VP | IM | VP | IM | VP | |
| Leucopenia | 1/13 (7.69%) | 2/11 (18.18%) | - | - | - | - |
| Diarrhea | 1/13 (7.69%) | - | - | - | - | - |
| Vomiting | 1/13 (7.69%) | 1/11 (9.09%) | - | 1/11 (9.09%) | - | - |
| Weight loss | - | - | - | - | - | - |
| Dysorexia/anorexia | 1/13 (7.69%) | 3/11 (27.27%) | - | - | - | - |
| Renal toxicity | - | - | - | - | - | - |
| Lethargy | - | - | - | - | - | - |
| Dermatologic | 1/13 (7.69%) | - | - | - | - | - |
| TOTAL | 5/13 (38.46%) | 6/11 (54.54%) ** | 0 | 1/11 (909%) | 0 | 0 |
* [24]. ** significantly higher than in IM dogs (p = 0.0331) (Fischer exact test).